Loading stock data…
OS Therapies Incorporated (OSTX)
$2.24+0.36 (+19.15%)
After Hours$2.21-0.03 (-1.32%)· Last close Jun 29
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OS Therapies Incorporated in the Healthcare sector is trading at $2.24 with a market capitalization of $77M. Wall Street consensus targets $9.40 (4 analysts), implying a +319.5% move over the next 12 months. The stock is currently 13% below its 52-week high of $2.57, remaining 34.1% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +319.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.17M↑ | -$11.99M↓ | -$6.88M↓ | -$4.84M↑ | -$5.00M |
| Net Income | -$10.40M↑ | -$13.46M↓ | -$6.88M↓ | -$4.54M↓ | -$3.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-H...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$76.60M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
2.00M
Recent News
OS Therapies to report significant survival benefit for OST-HER2 in osteosarcoma
Investing.com -- OS Therapies is expected to report today that its lead immunotherapy candidate, OST-HER2, has achieved a statistically significant overall survival benefit at 2.5 years in patients with fully resected pulmonary metastatic osteosarcoma, Investing.com has learned.
Wall Street Set to Open Higher Friday as Investors Await Powell's Speech at Jackson Hole
US stocks are set to open higher in Friday's trading session as investors look ahead to Federal Rese